Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Enhancement of an Auto-Injector Device for Self-Administration of Etanercept in Patients With Rheumatoid Arthritis Confers Emotional and Functional Benefits ; volume:7 ; number:3 ; day:4 ; month:6 ; year:2020 ; pages:537-552 ; date:9.2020
Rheumatology and therapy ; 7, Heft 3 (4.6.2020), 537-552, 9.2020
- Urheber
-
Rekaya, Naceur
Vicik, Steven M.
Hulesch, Bors T.
McDonald, Laura L.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-020-00216-5
- URN
-
urn:nbn:de:101:1-2020100122272895532349
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rekaya, Naceur
- Vicik, Steven M.
- Hulesch, Bors T.
- McDonald, Laura L.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
Correction to: The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
Satisfaction with Subcutaneous Golimumab and its Auto-Injector among Rheumatoid Arthritis Patients with Inadequate Response to Adalimumab or Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis
The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
SCHICK EVERSHARP INJECTOR RAZOR
Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept
Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis